Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma

Robertha C. Howell, Ekaterina Revskaya, Valeria Pazo, Joshua D. Nosanchuk, Arturo Casadevall, Ekaterina Dadachova

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Metastatic melanoma remains an incurable disease, and there is a great need for novel therapeutic modalities. We have recently identified melanin as a target for radionuclide therapy of melanoma and demonstrated the feasibility of this approach using a 188-rhenium (188Re)-radiolabeled melanin-binding decapeptide to fungal melanin known as 4B4. Although the results indicated that radiolabeled melanin-binding decapeptide had activity against melanoma, that peptide also manifested high kidney uptake and this might become a concern during clinical trials. We hypothesized that by identifying peptides with different amino acid composition against tumor melanin we might be able to decrease their kidney uptake. Using the Heptapeptide Ph.D.-7 Phage Display Library, we identified three heptapeptides that bind to human tumor melanin. These peptides were radiolabeled with 188Re via HYNIC ligand, and their comprehensive biodistribution in A2058 human metastatic melanoma tumor-bearing nude mice was compared to that of 188Re-4B4 decapeptide. While tumor uptake of heptapeptides was quite similar to that of 188Re-4B4 decapeptide, there was dramatically less uptake in the kidneys at both 3 h (6% ID/g vs 38%) and 24 h (2% ID/g vs 15%) postinjection. Administration of one of the generated heptapeptides, 188Re-HYNIC- AsnProAsnTrpGlyProArg, to A2058 human metastatic melanoma-bearing nude mice resulted in significant retardation of the tumor growth. Immunofluorescence showed that in spite of their relatively small size heptapeptides were not able to penetrate through the membranes of viable melanoma cells and bound only to extracellular melanin, which provides assurance that they will be safe to healthy melanin-containing tissues during radionuclide therapy. Thus, these heptapeptides appear to have potentially significant advantages for targeted therapy of melanoma relative to existing melanin-binding peptides.

Original languageEnglish (US)
Pages (from-to)1739-1748
Number of pages10
JournalBioconjugate Chemistry
Volume18
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Melanin
Peptide Library
Bacteriophages
Melanins
Radioisotopes
Peptides
Tumors
Melanoma
Rhenium
Display devices
Neoplasms
Bearings (structural)
Therapeutics
Kidney
Nude Mice
Libraries
Fluorescent Antibody Technique
Amino acids
Ligands
Clinical Trials

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry

Cite this

Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. / Howell, Robertha C.; Revskaya, Ekaterina; Pazo, Valeria; Nosanchuk, Joshua D.; Casadevall, Arturo; Dadachova, Ekaterina.

In: Bioconjugate Chemistry, Vol. 18, No. 6, 11.2007, p. 1739-1748.

Research output: Contribution to journalArticle

Howell, Robertha C. ; Revskaya, Ekaterina ; Pazo, Valeria ; Nosanchuk, Joshua D. ; Casadevall, Arturo ; Dadachova, Ekaterina. / Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. In: Bioconjugate Chemistry. 2007 ; Vol. 18, No. 6. pp. 1739-1748.
@article{d780a1e7ffb64cb1a2b9af3409cacf7f,
title = "Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma",
abstract = "Metastatic melanoma remains an incurable disease, and there is a great need for novel therapeutic modalities. We have recently identified melanin as a target for radionuclide therapy of melanoma and demonstrated the feasibility of this approach using a 188-rhenium (188Re)-radiolabeled melanin-binding decapeptide to fungal melanin known as 4B4. Although the results indicated that radiolabeled melanin-binding decapeptide had activity against melanoma, that peptide also manifested high kidney uptake and this might become a concern during clinical trials. We hypothesized that by identifying peptides with different amino acid composition against tumor melanin we might be able to decrease their kidney uptake. Using the Heptapeptide Ph.D.-7 Phage Display Library, we identified three heptapeptides that bind to human tumor melanin. These peptides were radiolabeled with 188Re via HYNIC ligand, and their comprehensive biodistribution in A2058 human metastatic melanoma tumor-bearing nude mice was compared to that of 188Re-4B4 decapeptide. While tumor uptake of heptapeptides was quite similar to that of 188Re-4B4 decapeptide, there was dramatically less uptake in the kidneys at both 3 h (6{\%} ID/g vs 38{\%}) and 24 h (2{\%} ID/g vs 15{\%}) postinjection. Administration of one of the generated heptapeptides, 188Re-HYNIC- AsnProAsnTrpGlyProArg, to A2058 human metastatic melanoma-bearing nude mice resulted in significant retardation of the tumor growth. Immunofluorescence showed that in spite of their relatively small size heptapeptides were not able to penetrate through the membranes of viable melanoma cells and bound only to extracellular melanin, which provides assurance that they will be safe to healthy melanin-containing tissues during radionuclide therapy. Thus, these heptapeptides appear to have potentially significant advantages for targeted therapy of melanoma relative to existing melanin-binding peptides.",
author = "Howell, {Robertha C.} and Ekaterina Revskaya and Valeria Pazo and Nosanchuk, {Joshua D.} and Arturo Casadevall and Ekaterina Dadachova",
year = "2007",
month = "11",
doi = "10.1021/bc060330u",
language = "English (US)",
volume = "18",
pages = "1739--1748",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "6",

}

TY - JOUR

T1 - Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma

AU - Howell, Robertha C.

AU - Revskaya, Ekaterina

AU - Pazo, Valeria

AU - Nosanchuk, Joshua D.

AU - Casadevall, Arturo

AU - Dadachova, Ekaterina

PY - 2007/11

Y1 - 2007/11

N2 - Metastatic melanoma remains an incurable disease, and there is a great need for novel therapeutic modalities. We have recently identified melanin as a target for radionuclide therapy of melanoma and demonstrated the feasibility of this approach using a 188-rhenium (188Re)-radiolabeled melanin-binding decapeptide to fungal melanin known as 4B4. Although the results indicated that radiolabeled melanin-binding decapeptide had activity against melanoma, that peptide also manifested high kidney uptake and this might become a concern during clinical trials. We hypothesized that by identifying peptides with different amino acid composition against tumor melanin we might be able to decrease their kidney uptake. Using the Heptapeptide Ph.D.-7 Phage Display Library, we identified three heptapeptides that bind to human tumor melanin. These peptides were radiolabeled with 188Re via HYNIC ligand, and their comprehensive biodistribution in A2058 human metastatic melanoma tumor-bearing nude mice was compared to that of 188Re-4B4 decapeptide. While tumor uptake of heptapeptides was quite similar to that of 188Re-4B4 decapeptide, there was dramatically less uptake in the kidneys at both 3 h (6% ID/g vs 38%) and 24 h (2% ID/g vs 15%) postinjection. Administration of one of the generated heptapeptides, 188Re-HYNIC- AsnProAsnTrpGlyProArg, to A2058 human metastatic melanoma-bearing nude mice resulted in significant retardation of the tumor growth. Immunofluorescence showed that in spite of their relatively small size heptapeptides were not able to penetrate through the membranes of viable melanoma cells and bound only to extracellular melanin, which provides assurance that they will be safe to healthy melanin-containing tissues during radionuclide therapy. Thus, these heptapeptides appear to have potentially significant advantages for targeted therapy of melanoma relative to existing melanin-binding peptides.

AB - Metastatic melanoma remains an incurable disease, and there is a great need for novel therapeutic modalities. We have recently identified melanin as a target for radionuclide therapy of melanoma and demonstrated the feasibility of this approach using a 188-rhenium (188Re)-radiolabeled melanin-binding decapeptide to fungal melanin known as 4B4. Although the results indicated that radiolabeled melanin-binding decapeptide had activity against melanoma, that peptide also manifested high kidney uptake and this might become a concern during clinical trials. We hypothesized that by identifying peptides with different amino acid composition against tumor melanin we might be able to decrease their kidney uptake. Using the Heptapeptide Ph.D.-7 Phage Display Library, we identified three heptapeptides that bind to human tumor melanin. These peptides were radiolabeled with 188Re via HYNIC ligand, and their comprehensive biodistribution in A2058 human metastatic melanoma tumor-bearing nude mice was compared to that of 188Re-4B4 decapeptide. While tumor uptake of heptapeptides was quite similar to that of 188Re-4B4 decapeptide, there was dramatically less uptake in the kidneys at both 3 h (6% ID/g vs 38%) and 24 h (2% ID/g vs 15%) postinjection. Administration of one of the generated heptapeptides, 188Re-HYNIC- AsnProAsnTrpGlyProArg, to A2058 human metastatic melanoma-bearing nude mice resulted in significant retardation of the tumor growth. Immunofluorescence showed that in spite of their relatively small size heptapeptides were not able to penetrate through the membranes of viable melanoma cells and bound only to extracellular melanin, which provides assurance that they will be safe to healthy melanin-containing tissues during radionuclide therapy. Thus, these heptapeptides appear to have potentially significant advantages for targeted therapy of melanoma relative to existing melanin-binding peptides.

UR - http://www.scopus.com/inward/record.url?scp=36849087052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849087052&partnerID=8YFLogxK

U2 - 10.1021/bc060330u

DO - 10.1021/bc060330u

M3 - Article

C2 - 17907769

AN - SCOPUS:36849087052

VL - 18

SP - 1739

EP - 1748

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 6

ER -